179 related articles for article (PubMed ID: 12719859)
1. [Development and pre-clinical aspects of pimecrolimus].
Stütz A; Grassberger M; Meingassner JG
Hautarzt; 2003 May; 54(5):405-12. PubMed ID: 12719859
[TBL] [Abstract][Full Text] [Related]
2. Pimecrolimus: a review.
Gupta AK; Chow M
J Eur Acad Dermatol Venereol; 2003 Sep; 17(5):493-503. PubMed ID: 12941081
[TBL] [Abstract][Full Text] [Related]
3. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
Stuetz A; Baumann K; Grassberger M; Wolff K; Meingassner JG
Int Arch Allergy Immunol; 2006; 141(3):199-212. PubMed ID: 16926539
[TBL] [Abstract][Full Text] [Related]
4. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
Stuetz A; Grassberger M; Meingassner JG
Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
[TBL] [Abstract][Full Text] [Related]
5. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M; Steinhoff M; Schneider D; Luger TA
Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Breuer K; Werfel T; Kapp A
Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
[TBL] [Abstract][Full Text] [Related]
7. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A.
Meingassner JG; Fahrngruber H; Bavandi A
J Invest Dermatol; 2003 Jul; 121(1):77-80. PubMed ID: 12839566
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of T-cell activation in vitro in human peripheral blood mononuclear cells by pimecrolimus and glucocorticosteroids and combinations thereof.
Winiski A; Wang S; Schwendinger B; Stuetz A
Exp Dermatol; 2007 Aug; 16(8):699-704. PubMed ID: 17620098
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
10. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
Jensen JM; Scherer A; Wanke C; Bräutigam M; Bongiovanni S; Letzkus M; Staedtler F; Kehren J; Zuehlsdorf M; Schwarz T; Weichenthal M; Fölster-Holst R; Proksch E
Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro.
Kalthoff FS; Winiski A; Fichtinger P; Schwendinger B; Wang S; Weishaeupl C; Stuetz A
Int Arch Allergy Immunol; 2007; 142(3):255-64. PubMed ID: 17114891
[TBL] [Abstract][Full Text] [Related]
13. Pimecrolimus for the treatment of inflammatory skin disease.
Wolff K; Stuetz A
Expert Opin Pharmacother; 2004 Mar; 5(3):643-55. PubMed ID: 15013932
[TBL] [Abstract][Full Text] [Related]
14. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids.
Kalthoff FS; Chung J; Musser P; Stuetz A
Clin Exp Immunol; 2003 Sep; 133(3):350-9. PubMed ID: 12930360
[TBL] [Abstract][Full Text] [Related]
15. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells.
Hoetzenecker W; Meingassner JG; Ecker R; Stingl G; Stuetz A; Elbe-Bürger A
J Invest Dermatol; 2004 Mar; 122(3):673-84. PubMed ID: 15086553
[TBL] [Abstract][Full Text] [Related]
17. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.
Reitamo S; Remitz A; Kyllönen H; Saarikko J
Am J Clin Dermatol; 2002; 3(6):381-8. PubMed ID: 12113647
[TBL] [Abstract][Full Text] [Related]
18. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
Ständer S; Ständer H; Seeliger S; Luger TA; Steinhoff M
Br J Dermatol; 2007 May; 156(5):1020-6. PubMed ID: 17388925
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.
Billich A; Aschauer H; Aszódi A; Stuetz A
Int J Pharm; 2004 Jan; 269(1):29-35. PubMed ID: 14698574
[TBL] [Abstract][Full Text] [Related]
20. [Antipruritic effects of pimecrolimus and tacrolimus].
Ständer S; Luger TA
Hautarzt; 2003 May; 54(5):413-7. PubMed ID: 12719860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
